0001181158-11-000004.txt : 20111206 0001181158-11-000004.hdr.sgml : 20111206 20111206091752 ACCESSION NUMBER: 0001181158-11-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111205 FILED AS OF DATE: 20111206 DATE AS OF CHANGE: 20111206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAGNUSON TERRY CENTRAL INDEX KEY: 0001181158 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-27570 FILM NUMBER: 111244576 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMACEUTICAL PRODUCT DEVELOPMENT INC CENTRAL INDEX KEY: 0001003124 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 561640186 STATE OF INCORPORATION: NC FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 BUSINESS PHONE: 9102510081 MAIL ADDRESS: STREET 1: 929 NORTH FRONT STREET CITY: WILMINGTON STATE: NC ZIP: 28401 4 1 edgar.xml PRIMARY DOCUMENT X0304 4 2011-12-05 1 0001003124 PHARMACEUTICAL PRODUCT DEVELOPMENT INC PPDI 0001181158 MAGNUSON TERRY 408 BAYBERRY DRIVE CHAPEL HILL NC 27514 1 0 1 0 Common Stock 2011-12-05 4 D 0 17633 33.25 D 0 D Stock Options (to buy) 24.26 2011-12-05 4 D 0 9090 0 D 9090 9090 0 D Stock Options (to buy) 28.52 2011-12-05 4 D 0 9095 0 D Common Stock 9095 0 D Stock Options (to buy) 24.52 2011-12-05 4 D 0 10496 0 D Common Stock 10496 0 D Stock Options (to buy) 19.19 2011-12-05 4 D 0 14053 0 D Common Stock 14053 0 D Stock Options (to buy) 41.32 2011-12-05 4 D 0 6485 0 D Common Stock 6485 0 D Stock Options (to buy) 32.67 2011-12-05 4 D 0 6341 0 D Common Stock 6341 0 D Stock Options (to buy) 12.37 2011-12-05 4 D 0 12421 0 D Common Stock 12421 0 D Stock Options (to buy) 13.12 2011-12-05 4 D 0 16561 0 D Common Stock 16561 0 D Stock Options (to buy) 15.28 2011-12-05 4 D 0 16561 0 D Common Stock 16561 0 D Stock Options (to buy) 22.98 2011-12-05 4 D 0 5650 0 D Common Stock 5650 0 D Stock Options (to buy) 34.18 2011-12-05 4 D 0 4113 0 D Common Stock 4113 0 D Pursuant to the Agreement and Plan of Merger (the "Agreement") by and among Pharmaceutical Prodcut Development, Inc., Jaguar Holdings, LLC and Jaguar Merger Sub, Inc. dated as of October 2, 2011, on the effective date of the merger contemplated by the Agreement (the "Merger"), each of these shares of common stock was automatically converted into the right to receive $33.25. These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. The options were scheduled to vest in three equal increments on 7/30/2011, 7/30/2012 and 7/30/2013 but vesting was accelerated due to the Merger. These stock options were cancelled pursuant to the Merger in exchange for a cash payment equal to the difference (if any) between the exercise price of the stock options and $33.25 multiplied by the number of shares subject to such stock options less any applicable withholding taxes. Lisa C. Noecker attorney-in-fact for Terry Magnuson 2011-12-06